Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.6.1.2 (
alanine aminotransferase
)
26,722
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ischemia-reperfusion injury (IRI) of the liver is a primary cause of post-liver-surgery complications and ischemic preconditioning (IPC) has been verified to protect against ischemia-reperfusion injury.
TIM-4
activation plays an important role in macrophage mediated hepatic IRI. This study aimed to determine whether IPC protects against hepatic IRI through inhibiting
TIM-4
activation. In this study, a model of warm liver ischemia (90 min) and reperfusion for 6 h was used. Mice were subjected to ischemia-reperfusion injury with or without ischemic preconditioning and
TIM4
blocking antibody. Western blot was determined to detect the expression of
TIM4
protein and mitochondrial apoptosis-related protein expression. Liver function was evaluated using the level of
alanine transaminase
(
ALT
) and aspartate transaminase (AST), cell apoptosis and pathological examination. We found that compared with the control group, ischemic preconditioning reduced IRI by decreasing hepatocyte apoptosis,
ALT
, AST, CD68 and CD3 positive cells, tissue myeloperoxidase activity(MPO), and downregulating
TIM-4
expression.
TIM4
blocking could reduce CD68 and CD3 positive cells in liver. Furthermore, activated monocytes transfusion significantly abolished the protect effect of IPC with increased hepatocyte apoptosis,
ALT
, AST, CD68 and CD3 positive cells while
TIM-4
knockdown monocytes lost this effect. These results suggested that IPC protects against hepatic IRI by downregulating
TIM-4
and indicated
TIM-4
would be a novel therapeutic target to minimize IRI.
...
PMID:Hepatic Ischemic Preconditioning Alleviates Ischemia-Reperfusion Injury by Decreasing TIM4 Expression. 3012 68